SCHEMBL18173744

SCHEMBL18173744

Cc1ccc2c(c1)Nc1ccccc1S(=O)(=O)C2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLCG1 P19174 1/20 0.53
KMT2A Q03164 5/20 0.44
MEN1 O00255 4/20 0.44
NOX1 Q9Y5S8 1/20 0.44
CSNK1G1 Q9HCP0 1/20 0.41
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ROS1 P08922 1/20 0.40
CDK5 Q00535 1/20 0.40
ACVR1 Q04771 1/20 0.40
LRRK2 Q5S007 1/20 0.40
MAPT P10636 2/20 0.39
POLB P06746 1/20 0.39
HTR5A P47898 2/20 0.39
CA4 P22748 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18173741 0.82 PLCG1 (0.65) PLCG1KMT2AMEN1NOX1CA12
SCHEMBL15500319 0.76 KMT2A (0.68) PLCG1KMT2AMEN1NOX1CSNK1G1
SCHEMBL30105853 0.72 MAPT (0.62) KMT2AMEN1CSNK1G1KDM4EALDH1A1
SCHEMBL6969939 0.72 MAPT (0.62) KMT2AMEN1CSNK1G1KDM4EALDH1A1
SCHEMBL12060281 0.71 PLCG1 (0.59) PLCG1CSNK1G1CA12CA1CA2
SCHEMBL18173632 0.70
SCHEMBL88748 0.70 PLCG1 (1.00) PLCG1KMT2AMEN1NOX1CA12
SCHEMBL11927572 0.68 HTR5A (0.53) CSNK1G1ALDH1A1HSD17B10ROS1CDK5
SCHEMBL6966954 0.68 HTR5A (0.53) KMT2AMEN1CSNK1G1CA9KDM4E
SCHEMBL12702063 0.68 CA1 (0.39) CA12CA1CA2CA9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3250035-B1 COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS ALLGENESIS BIOTHERAPEUTICS INC (TW) 2023-01-25 EP disclosed
US-10870635-B2 Compounds and their use as BACE1 inhibitors ALLGENESIS BIOTHERAPEUTICS, INC. (TW) 2020-12-22 US disclosed
US-20180201604-A1 COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS ALLGENESIS BIOTHERAPEUTICS, INC. (TW) 2018-07-19 US disclosed
EP-3250035-A1 COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS Allgenesis Biotherapeutics Inc. (TW) 2017-12-06 EP disclosed
WO-2016172255-A1 COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS ALLGENESIS BIOTHERAPEUTICS, INC. (TW) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10870635-B2 Compounds and their use as BACE1 inhibitors BACE1, BACE2, APP PLCG1 3539/4885KMT2A 3744/4885MEN1 1510/4885
US-20180201604-A1 COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS BACE1, BACE2, APP PLCG1 3592/4885KMT2A 3811/4885MEN1 1461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.